Nural is a postdoctoral researcher at the ithree institute, specialising in the field of microbiology. Nural’s research interest is in understanding how bacteria cause infections and disease and finding new approaches to slow down the rise of antimicrobial resistance. Her expertise is in the medicinal properties of honey – a potent killer of bacteria – and its potential as a novel, cheap and accessible solution for the treatment of infections.
Nural’s research focuses on two main areas concerning the use of honey: 1) as a topical treatment for chronic wounds and skin infections; and 2) as a prebiotic food to remediate the gut microbiome to help combat the onset and progression of gut-related diseases.
Nural is equally passionate about doing research that has direct positive impacts for society, as she is about communicating her research to as broad an audience as possible.
- PhD (2015), Microbiology, University of New South Wales, Australia.
- BSc Hons I (2008), Majors: Molecular Biotechnology and Microbiology, University of Sydney, Australia.
Grants and awards
- Principal Investigator, Increasing the value of Australian honey as a health food, AgriFutures Australia (2018 - 2021)
- Co-investigator, Cross-species gene regulation: missing link in the wound healing properties of manuka honey, Faculty of Engineering Blue Sky Research Scheme (2018 - 2019).
- UTS Vice Chancellor’s Research Excellence Award Winner in the Early Career Researcher category (2018)
- FameLab Winner and Audience Choice Award for Best Young Science Communicator in Australia; and International Runner-Up Award (Cheltenham Science Festival, UK) (2017). FameLab is the largest science communication competition in the world.
- Australian Society for Microbiology (ASM) Postdoctoral Award Winner of the NSW-ACT branch award (2017).
- Best Oral Presentation Award at FOSTER UTS conference (2017).
- TEDxSydney Named one of the top five young change-makers for her research (by Junkee) (2017).
- UTS Early Career Researcher Showcase Award Winner of the best research presentation award (2016).
- Australian Postgraduate Award (2011 - 2015).
Member of the Australian Society for Microbiology.
Can supervise: YES
Lehmann, DM, Krishnakumar, K, Batres, MA, Hakola-Parry, A, Cokcetin, N, Harry, E & Carter, DA 2019, 'A cost-effective colourimetric assay for quantifying hydrogen peroxide in honey', Access Microbiology.View/Download from: UTS OPUS or Publisher's site
Liu, MY, Cokcetin, NN, Lu, J, Turnbull, L, Carter, DA, Whitchurch, CB & Harry, EJ 2018, 'Rifampicin-Manuka Honey Combinations Are Superior to Other Antibiotic-Manuka Honey Combinations in Eradicating Staphylococcus aureus Biofilms.', Frontiers in Microbiology, vol. 8, pp. 1-12.View/Download from: UTS OPUS or Publisher's site
Chronic wound infections are a major burden to both society and the health care industry. Bacterial biofilms are the major cause of chronic wound infections and are notoriously recalcitrant to treatments with antibiotics, making them difficult to eradicate. Thus, new approaches are required to combat biofilms in chronic wounds. One possible approach is to use drug combination therapies. Manuka honey has potent broad-spectrum antibacterial activity and has previously shown synergistic activity in combination with antibiotics against common wound pathogens, including Staphylococcus aureus. In addition, manuka honey exhibits anti-biofilm activity, thereby warranting the investigation of its potential as a combination therapy with antibiotics for the topical treatment of biofilm-related infections. Here we report the first use of MacSynergy II to investigate the response of established S. aureus (strain NCTC 8325) biofilms to treatment by combinations of Medihoney (medical grade manuka honey) and conventional antibiotics that are used for preventing or treating infections: rifampicin, oxacillin, fusidic acid, clindamycin, and gentamicin. Using checkerboard microdilution assays, viability assays and MacSynergy II analysis we show that the Medihoney-rifampicin combination was more effective than combinations using the other antibiotics against established staphylococcal biofilms. Medihoney and rifampicin were strongly synergistic in their ability to reduce both biofilm biomass and the viability of embedded S. aureus cells at a level that is likely to be significant in vivo. Other combinations of Medihoney and antibiotic produced an interesting array of effects: Medihoney-fusidic acid treatment showed minor synergistic activity, and Medihoney-clindamycin, -gentamicin, and -oxacillin combinations showed overall antagonistic effects when the honey was used at sub-inhibitory concentration, due to enhanced biofilm formation at these concentrations which could not be counter...
Carter, DA, Blair, SE, Cokcetin, NN, Bouzo, D, Brooks, P, Schothauer, R & Harry, EJ 2016, 'Therapeutic Manuka Honey: No Longer So Alternative', FRONTIERS IN MICROBIOLOGY, vol. 7.View/Download from: UTS OPUS or Publisher's site
Cokcetin, NN, Pappalardo, M, Campbell, LT, Brooks, P, Carter, DA, Blair, SE & Harry, EJ 2016, 'The Antibacterial Activity of Australian Leptospermum Honey Correlates with Methylglyoxal Levels', PLOS ONE, vol. 11, no. 12.View/Download from: UTS OPUS or Publisher's site
Blair, S, Cokcetin, N, Harry, L & Carter, D 2009, 'The unusual antibacterial activity of medical-grade Leptospermum honey: antibacterial spectrum, resistance and transcriptome analysis', European Journal of Clinical Microbiology & Infecti..., vol. 28, no. 10, pp. 1199-1208.View/Download from: UTS OPUS or Publisher's site
There is an urgent need for new, effective agents in topical wound care, and selected honeys show potential in this regard. Using a medical-grade honey, eight species of problematic wound pathogens, including those with high levels of innate or acquired antibiotic resistance, were killed by 4.0-14.8% honey, which is a concentration that can be maintained in the wound environment. Resistance to honey could not be induced under conditions that rapidly induced resistance to antibiotics. Escherichia coli macroarrays were used to determine the response of bacterial cells to a sub-lethal dose of honey. The pattern of gene expression differed to that reported for other antimicrobial agents, indicating that honey acts in a unique and multifactorial way; 78 (2%) genes were upregulated and 46 (1%) genes were downregulated more than two-fold upon exposure to the medical-grade honey. Most of the upregulated genes clustered into distinct functional regulatory groups, with many involved in stress responses, and the majority of downregulated genes encoded for products involved in protein synthesis. Taken together, these data indicate that honey is an effective topical antimicrobial agent that could help reduce some of the current pressures that are promoting antibiotic resistance.